NasdaqGM:WVEPharmaceuticals
A Look At Wave Life Sciences (WVE) Valuation After INLIGHT Phase 1 Obesity Data Disappoints Investors
Investor reaction to INLIGHT Phase 1 update
Wave Life Sciences (WVE) shares sold off after the company released new interim data from the Phase 1 INLIGHT trial of its obesity candidate WVE-007, with results falling short of market expectations.
The update highlighted clinically meaningful reductions in visceral fat and waist circumference. However, investor response reflected concerns about how these findings compare with existing obesity treatments and what that might imply for future...